Breeze Acquisition Corp. II: insider trades · United States · SEC (Form 4)

About Breeze Acquisition Corp. II

Breeze Acquisition Corp. II is a special purpose acquisition company, or SPAC, formed in the Cayman Islands and focused on the U.S. capital markets. The company is listed in the United States on the Nasdaq Global Market, placing it in the small-cap, event-driven segment of the public markets rather than in a traditional operating business category. Its business address is 955 W. John Carpenter Fwy, Suite 100-929, Irving, Texas, United States. Breeze II was incorporated on August 20, 2025 for the purpose of completing a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2095443/000121390025111161/0001213900-25-111161-index.htm)) Strategically, Breeze II is not limited to any single industry or geography, but its SEC disclosures indicate that management intends to focus on companies with global operations and differentiated technology or capabilities, particularly in healthcare, biotechnology, advanced manufacturing, robotics, artificial intelligence, and related sectors. That makes Breeze II a relatively thematic SPAC sponsor, aiming to source a target that can support a compelling de-SPAC story and potentially attract institutional interest. As of the latest filings reviewed, the company has not selected a definitive target business for its initial transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2095443/000121390026018942/ea0273293-s1a1_breeze2.htm)) A key part of Breeze II’s investment narrative is the track record of Breeze Holdings Acquisition Corp. (“Breeze I”), the predecessor vehicle. Breeze I completed a business combination with YD Biopharma Limited; the combined company subsequently began trading on Nasdaq as YD Bio Limited under the symbols YDES and YDESW. For investors, that prior transaction matters because it demonstrates that Breeze’s management team has already executed a cross-border SPAC combination and navigated the listing process through completion. At the same time, the historical outcome of Breeze I should not be viewed as a guarantee of future performance for Breeze II. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2095443/000121390026018942/ea0273293-s1a1_breeze2.htm)) From a capital markets perspective, Breeze II follows the classic SPAC model: IPO proceeds are held in trust, public shareholders receive redemption protections, and the company must complete a business combination within the contractual timeframe or liquidate. The IPO was priced in May 2026, and the offering structure included units composed of one ordinary share and one right. This structure underscores the company’s pre-revenue, pre-operating profile and means that, for equity investors, the key valuation driver will be the quality, price, and closing probability of the future acquisition target rather than current operating metrics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2095443/000121390026018942/ea027329301ex10-1_breeze2.htm)) Recent SEC filings mainly reflect IPO execution, trust-account mechanics, governance steps, and ongoing preparation for a potential business combination. In short, Breeze Acquisition Corp. II is a Nasdaq-listed U.S.-facing SPAC with no operating business of its own yet; its market position will ultimately be determined by the target it identifies and the transaction terms it can secure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2095443/000121390026057783/ea0290760-8k_breeze2.htm?utm_source=openai))